Reshaping the HIV treatment and prevention landscape

Industry leading pipeline Largest number of mid/late-stage assets in areas of significant unmet medical need gsk gsk 6 Company A 5 7 Company B LO Company C 2 5 7 Company D 4 1 Company E 2 2 4 Company F 3 1 4 Phase 2 Phase 3 / Registrational 5 LO 10 12 7 12 RSV 16 177k hospitalisations, 14k deaths per year in 65+ adults annually in the US1 Meningitis 1.2m cases of IMD annually with ~10% mortality rate Antimicrobial Resistance 700k deaths annually & est. 8x increase within 30 years2 COVID-19 ~2bn cases and close to 3m deaths globally to date 59 Note: Includes Phase 2 and Phase 3 trials for non-cancer vaccines Sources: Company websites and Clinicaltrials.gov (March 2021); Registration as reported on company websites (March 2021) 1. Centers for Disease Control and Prevention (CDC), 2018. RSV in older adults and adults with chronic medical conditions. https://www.cdc.gov/rsv/high-risk/older-adults.html (accessed July 2019); 2. Interagency Coordination Group on Antimicrobial Resistance, 'No time to wait: securing the future from drug-resistant infections', April 2019. Available at https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/ ). IMD Invasive Meningococcal Disease

View entire presentation